 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | mRNA-1215 / Moderna
Trial completion: Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults (clinicaltrials.gov) - Sep 24, 2024
P1, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed
- || mRNA-1215 / Moderna
Review, Journal: Current progress towards prevention of Nipah and Hendra disease in humans: A scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials. (Pubmed Central) - Feb 28, 2024
Multiple vaccine candidates and one mAb candidate have reached the stage of human clinical trials and are reviewed here. Monitoring progress during evaluation of these candidates and candidates entering clinical trials in the future can help highlight many of the challenges that remain.
- | mRNA-1215 / Moderna
Enrollment closed, Trial completion date, Trial primary completion date: Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults (clinicaltrials.gov) - Sep 13, 2023
P1, N=50, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Monitoring progress during evaluation of these candidates and candidates entering clinical trials in the future can help highlight many of the challenges that remain. Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
- | mRNA-1215 / Moderna
New P1 trial: Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults (clinicaltrials.gov) - Jun 1, 2022
P1, N=50, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)